Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Biosino Bio-Technology and Science Days Payable?
Biosino Bio-Technology and ScienceHKSE:08247 -2.62%37 Days Payable is 222.38 as of Dec. 2025, which is 2% above its 10-year median of 218.55. GuruFocus rates HKSE:08247 with a GF Score™ of 37/100 and a GF Value™ of HK$0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, Biosino Bio-Technology and Science ranks better than 81.48% on this metric.
HKSE:08247'
s Days Payable Range Over the Past 10 Years
Min: 74.91 Med: 218.55 Max: 283.75
Current: 235.3
During the past 13 years, Biosino Bio-Technology and Science's highest Days Payable was 283.75. The lowest was 74.91. And the median was 218.55.
HKSE:08247's Days Payable is ranked better than 81.48% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.92
vs HKSE:08247: 235.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science Days Payable Chart
HKSE:08247 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosino Bio-Technology and Science Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's Days Payable distribution charts can be found below:
* The bar in red indicates where Biosino Bio-Technology and Science's Days Payable falls into.
Biosino Bio-Technology and Science Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science (HKSE:08247) has a Days Payable of 222.38 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biosino Bio-Technology and Science and its competitors. This is near median its historical median of 218.55. Over the past decade, Biosino Bio-Technology and Science's Days Payable has ranged from 74.91 to 283.75. According to the industry distribution chart, Biosino Bio-Technology and Science ranks #35 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 18.5%.
Is Biosino Bio-Technology and Science's Days Payable too high?
Biosino Bio-Technology and Science's current Days Payable of 222.38 is near median its 10-year median of 218.55. Over the past 10 years, this metric has ranged from a low of 74.91 to a high of 283.75. The Medical Diagnostics & Research industry median Days Payable is 64.92. Biosino Bio-Technology and Science's value of 222.38 is 242.5% above this industry median. Based on the distribution chart, Biosino Bio-Technology and Science ranks #35 out of 189 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biosino Bio-Technology and Science ranks #35 out of 189 companies for Days Payable. This places Biosino Bio-Technology and Science in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.92. Biosino Bio-Technology and Science's value of 222.38 is 242.5% above this benchmark. Historically, Biosino Bio-Technology and Science's own Days Payable has ranged from 74.91 to 283.75 over the past decade. While the company's 10-year median is 218.55 vs. the industry median of 64.92, Biosino Bio-Technology and Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.92, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosino Bio-Technology and Science's current Days Payable of 222.38 is 242.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biosino Bio-Technology and Science and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosino Bio-Technology and Science's current Days Payable is 222.38, which is near median its own 10-year median of 218.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.17 — trading 619.3% above its estimated fair value. The current Days Payable is 222.38, which is near median its 10-year median of 218.55 and 242.5% above the Medical Diagnostics & Research industry median of 64.92. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current Days Payable is 222.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued.
The current stock price of HK$3.17 is trading 619.3% above its estimated GF Value™ of HK$0.44.
GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.
Key valuation signals for HKSE:08247:
Days Payable: 222.38 (near median its 10-year median of 218.55)
GF Value™: HK$0.44 vs. price of HK$3.17 (619.3% above fair value)
Industry Position: 242.5% above the Medical Diagnostics & Research median (#35 of 189)
No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score
Get the complete analysis for HKSE:08247
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08247 has been successfully added to your 
